GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer

Author:

Galan Alba,Papaluca Arturo,Nejatie Ali,Matanes Emad,Brahimi Fouad,Tong Wenyong,Hachim Ibrahim Yaseen,Yasmeen Amber,Carmona Euridice,Klein Kathleen Oros,Billes Sonja,Dawod Ahmed E.,Gawande Prasad,Jeter Anna Milik,Mes-Masson Anne-Marie,Greenwood Celia M. T.,Gotlieb Walter H.,Saragovi H. Uri

Abstract

BackgroundOvarian cancer (OC) is the deadliest gynecological cancer, often diagnosed at advanced stages. A fast and accurate diagnostic method for early-stage OC is needed. The tumor marker gangliosides, GD2 and GD3, exhibit properties that make them ideal potential diagnostic biomarkers, but they have never before been quantified in OC. We investigated the diagnostic utility of GD2 and GD3 for diagnosis of all subtypes and stages of OC.MethodsThis retrospective study evaluated GD2 and GD3 expression in biobanked tissue and serum samples from patients with invasive epithelial OC, healthy donors, non-malignant gynecological conditions, and other cancers. GD2 and GD3 levels were evaluated in tissue samples by immunohistochemistry (n=299) and in two cohorts of serum samples by quantitative ELISA. A discovery cohort (n=379) showed feasibility of GD2 and GD3 quantitative ELISA for diagnosing OC, and a subsequent model cohort (n=200) was used to train and cross-validate a diagnostic model.ResultsGD2 and GD3 were expressed in tissues of all OC subtypes and FIGO stages but not in surrounding healthy tissue or other controls. In serum, GD2 and GD3 were elevated in patients with OC. A diagnostic model that included serum levels of GD2+GD3+age was superior to the standard of care (CA125, p<0.001) in diagnosing OC and early-stage (I/II) OC.ConclusionGD2 and GD3 expression was associated with high rates of selectivity and specificity for OC. A diagnostic model combining GD2 and GD3 quantification in serum had diagnostic power for all subtypes and all stages of OC, including early stage. Further research exploring the utility of GD2 and GD3 for diagnosis of OC is warranted.

Funder

Canadian Institutes of Health Research

Réseau Québécois de Recherche sur les Médicaments

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Bioactive sphingolipids as emerging targets for signal transduction in cancer development;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Editorial: Pharmacology of gangliosides;Frontiers in Pharmacology;2024-07-18

3. Regulation of sialic acid metabolism in cancer;Carbohydrate Research;2024-05

4. Serum Lipidome Profiling Reveals a Distinct Signature of Ovarian Cancer in Korean Women;Cancer Epidemiology, Biomarkers & Prevention;2024-02-27

5. Glycobiology of Cancer;Pathogens Associated with the Development of Cancer in Humans;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3